|
It was my understanding that this trial is NOT targeted toward women with metastatic breast cancer. My understanding is that this vaccine is being tested in HER2 positive women who are currently NED but at high risk for recurrence and have never had a metastisis. The goal is to try to find out if the vaccine prevents spread.
I also understand that the reason they are testing this out in non-metastatic women without current evidence of disease is that in theory this particular vaccine may work better in women with a low disease load.
__________________
Janelle
Diagnosed October 2006 at age 37 wtih grade 3 IDC and high grade DCIS
Stage 1c triple positive, no node involvement but
vascular invasion
multifocal disease
Lumpectomy November, 2006
A/C every 3 weeks (started Jan., 2007 and finished March 2007); followed weekly Taxol (finished June 2007) concurrent with Herceptin (finished March 2008);
Bilateral Mast with immediate recon in Sept 2007; finished recon Dec. 2007
Started 5 years of tamoxifen Nov. 2007; started peptide vaccine clinical trial at MD Anderson October 2008 and finished active part of trial in April 2009 (monthly injections of AE37 peptitde (HLA type specific) with GM-CSF or GM-CSF alone depending on if I was in experimental or control group); started Zometa infusions June 25, 2009- 4mg every 6 months for 3 years (taking it "off-label" to try to prevent mets)
|